AnaptysBio Inc. (ANAB)
20.55
1.49 (7.82%)
At close: Apr 17, 2025, 3:59 PM
7.82% (1D)
| Bid | 16.88 |
| Market Cap | 630.2M |
| Revenue (ttm) | 91.28M |
| Net Income (ttm) | -145.23M |
| EPS (ttm) | -5.12 |
| PE Ratio (ttm) | -4.01 |
| Forward PE | -4.14 |
| Analyst | Buy |
| Ask | 21.5 |
| Volume | 590,515 |
| Avg. Volume (20D) | 1,056,846 |
| Open | 19.24 |
| Previous Close | 19.06 |
| Day's Range | 19.24 - 20.72 |
| 52-Week Range | 12.21 - 41.31 |
| Beta | -0.09 |
About ANAB
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2017
Employees 136
Stock Exchange NASDAQ
Ticker Symbol ANAB
Website https://www.anaptysbio.com
Analyst Forecast
According to 9 analyst ratings, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is $36, which is an increase of 75.18% from the latest price.
Stock ForecastsNext Earnings Release
AnaptysBio Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+9.54%
AnaptysBio shares are trading higher after the com...
Unlock content with
Pro Subscription
2 months ago
+30.45%
AnaptysBio shares are trading higher after the company announced statistically significant week 12 data from the Phase 2b trial of rosnilimab in moderate-to-severe rheumatoid arthritis.
